Guidelines on neuraminidase inhibitors in children are not supported by evidenceBMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7433.227 (Published 22 January 2004) Cite this as: BMJ 2004;328:227
- Mkael Symmonds, preregistration house officer (email@example.com),
- Nicholas J Matheson, preregistration house officer,
- Anthony Harnden, university lecturer
- Department of Surgery, Ayr Hospital, Ayr KA6 6DX
- Department of Medicine, John Radcliffe Hospital, Oxford OX3 9DU
- Department of Primary Health Care, Institute of Health Sciences, Oxford OX3 7LF
EDITOR—Guidelines from the National Institute for Clinical Excellence (NICE) on the use of neuraminidase inhibitors recommend oseltamivir for the treatment of at risk children with influenza-like illness of fewer than 48 hours' duration—for example, those with underlying chronic respiratory disease.1 The drug is not recommended for otherwise healthy children.
In our systematic review on the use of neuraminidase …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial